Large Scale Suspension Culture of Mammalian Cells

Industrial Scale Suspension Culture of Living Cells

Volumn 9783527335473, Issue , 2014, Pages 410-462

  Alldread, Richard M ^a   Birch, John R ^b   Metcalfe, Hilary K ^c   Farid, Suzanne ^d   Racher, Andrew J ^c   Young, Robert J ^c   Khan, Mohsan ^c  

^a CENTRE FOR PROCESS INNOVATION   (United Kingdom)

^b Henley on Thames   (United Kingdom)

^c LONZA AG   (Switzerland)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Biopharmaceutical; Bioreactor; Biotherapeutic protein; Cell line selection; Chinese hamster ovary cell; Culture media; Economics; Expression vector; Large scale culture; Mammalian cell; Monoclonal antibody; Perfusion reactor; Process control; Process design; Productivity; Recombinant DNA technology; Recombinant protein; Regulation; Single use bioreactor; Stirred tank bioreactor

Indexed keywords

ANIMAL CELL CULTURE; BIOCONVERSION; CELLS; MAMMALS; MONOCLONAL ANTIBODIES; PROCESS CONTROL; PROCESS DESIGN; PRODUCTIVITY; RECOMBINANT PROTEINS;

BIOPHARMACEUTICALS; BIOTHERAPEUTIC PROTEIN; BIOTHERAPEUTICS; CELL LINE SELECTION; CELL LINES; CHINESE HAMSTER OVARY CELLS; CULTURE MEDIUM; EXPRESSION VECTORS; LARGE-SCALE CULTURES; LINE SELECTIONS; MAMMALIAN CELLS; PERFUSION REACTOR; REGULATION; SINGLE USE; SINGLE USE BIOREACTOR; STIRRED TANK BIOREACTORS;

BIOREACTORS;

EID: 84927111316     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527683321.ch12     Document Type: Chapter

References (161)

1. Alberts, B. et al. (2002) Some Landmarks in the Development of Tissue and Cell Culture in Molecular Biology of the Cell, 4th edn, Garland Science, New York.
2. Scherer, W.F., Syverton, J.T., and Gey, G.O. (1953) Studies on the propagation in vitro of poliomyelitis viruses. IV. Viral multiplication in a stable strain of human malignant epithelial cells (strain HeLa) derived from an epidermoid carcinoma of the cervix. J. Exp. Med., 97, 695-710.
3. Eagle, H. (1955) The minimum vitamin requirements of the L and HeLa cells in tissue culture, the production of specific vitamin defi ciencies, and their cure. J. Exp. Med., 102, 595-600.
4. Higuchi, K. (1963) Studies on the nutrition and metabolism of animal cells in serum-free media. I. Serum-free monolayer cultures. J. Infect. Dis., 112, 213-220.
5. Salk, J.E. (1953) Immunization against poliomyelitis. Pediatr. Clin. North Am., 1, 49-51.
6. Tjio, J.H. and Puck, T.T. (1958) Genetics of somatic mammalian cells. II. Chromosomal constitution of cells in tissue culture. J. Exp. Med., 108, 259-268.
7. Carrel, A. (1913) Arti ficial activation of the growth in vitro of connective tissue. J. Exp. Med., 17, 14-19.
8. Sanford, K.K., Earle, W.R., and Likely, G.D. (1948) The growth in vitro of single isolated tissue cells. J. Natl. Cancer Inst., 9, 229-246.
9. Owens, O.v.H., Gey, M.K., and Gey, G.O. (1953) A new method for the cultivation of mammalian cells suspended in agitated fl uid medium. Proc. Am. Assoc. Cancer Research, 1, 41.
10. McLimans, W.F., Giardinello, F.E., Davis, E.V., Kucera, C.J., and Rake, G.W. (1957) Submerged culture of mammalian cells: the five liter fermentor. J. Bacteriol., 74, 768-774.
11. Polatnick, J. and Bachrach, H.L. (1964) Production and purification of milligram amounts of foot-and-mouth disease virus from baby hamster kidney cell cultures. Appl. Microbiol., 12, 368-373.
12. Ham, R.G. (1965) Clonal growth of mammalian cells in a chemically defined, synthetic medium. Proc. Natl. Acad. Sci. USA, 53, 288-293.
13. Kohler, G. and Milstein, C. (1975) Continuous cultures of fused cells secreting antibody of predefi ned specificity. Nature, 256, 495-497.
14. Wigler, M. et al. (1977) Transfer of purified herpes virus thymidine kinase gene to cultured mouse cells. Cell, 11, 223-232.
15. Evaluate Pharma (HTDB 2011) Biomanufacturing Report.
16. Jacquet, P., Schwarzbach, E., and Oren, I. (2011) The new face of blockbuster drugs. In Vivo: Business & Med. Rep. 29 (5), 2-7.
17. Genetic Engineering & Biotechnology News, March 5, 2013. Available at http://www.genengnews.com/insight-andintelligence/top-20-best-selling-drugs-of-2012/77899775/ (accessed March 17, 2014).
18. Zurdo, J. (2013) Developability assessment as an early de-risking tool for biopharmaceutical development. Pharm. Bioprocess., 1, 29-50.
19. Smales, C.M., Dinnis, D.M., Stansfield, S.H., Alete, D.E. et al. (2004) Comparative proteomic analysis of GS-NS0 murine myeloma cell lines with varying recombinant monoclonal antibody production rate. Biotechnol. Bioeng., 88, 474-488.
20. Birch, J.R., Mainwaring, D.O., and Racher, A.J. (2005) Use of the Glutamine Synthetase (GS) Expression System for the Rapid Development of Highly Productive Mammalian Cell Processes, in Modern Biopharmaceuticals (ed. J. Knäblein), Wiley-VCH Verlag GmbH, Weinheim, pp. 809-832.
21. Birch, J.R. and Racher, A.J. (2006) Antibody production. Adv. Drug Deliv. Rev., 58, 671-685.
22. Kalwy, S., Rance, J., and Young, R. (2006) Toward more efficient protein expression: keep the message simple. Mol. Biotechnol., 34, 151-156.
23. Knappskog, S., Ravneberg, H., Gjerdrum, C., Trobetae, C. et al. (2006) The level of synthesis and secretion of Gaussia princeps luciferase in transfected CHO cells is heavily dependent on the choice of signal peptide. J. Biotechnol., 128, 705-715.
24. Kober, L., Zehe, C., and Bode, J. (2012) Development of a novel ER stress based selection system for the isolation of highly productive clones. Biotechnol. Bioeng., 109, 2599-2611.
25. Alete, D.E., Racher, A.J., Birch, J.R., Stansfield, S.H. et al. (2005) Proteomic analysis of enriched microsomal fractions from GS-NS0 murine myeloma cells with varying secreted recombinant monoclonal antibody productivities. Proteomics, 5, 4689-4704.
26. Dinnis, D.M., Stansfield, S.H., Schlatter, S., Smales, C.M. et al. (2006) Functional proteomic analysis of GS-NS0 murine myeloma cell lines with varying recombinant monoclonal antibody production rate. Biotechnol. Bioeng., 94, 830-841.
27. Stansfield, S.H., Allen, E.E., Dinnis, D.M., Racher, A.J. et al. (2007) Dynamic analysis of GS-NS0 cells producing a recombinant monoclonal antibody during fed-batch culture. Biotechnol. Bioeng., 97, 410-424.
28. O'Callaghan, P.M., McLeod, J., Pybus, L.P., Lovelady, C.S. et al. (2010) Cell linespecific control of recombinant monoclonal antibody production by CHO cells. Biotechnol. Bioeng., 106, 938-951.
29. McLeod, J., O'Callaghan, P.M., Pybus, L.P., Wilkinson, S.J. et al. (2011) An empirical modeling platform to evaluate the relative control discrete CHO cell synthetic processes exert over recombinant monoclonal antibody production process titre. Biotechnol. Bioeng., 108, 2193-2204.
30. Davies, S.L., Lovelady, C.S., Grainger, R.K., Racher, A.J. et al. (2013) Functional heterogeneity and heritability in CHO cell populations. Biotechnol. Bioeng., 110, 260-274.
31. Hu, Z., Guo, D., Yip, S.S.M., Zhan, D. et al. (2013) Chinese hamster ovary K1 host cell enables stable cell line development for antibody molecules which are difficult to express in DUXB11-derived dihydrofolate reductase deficient host cell. Biotechnol. Prog., 29, 980-985.
32. Wurm, F.M. (2004) Production of recombinant protein therapeutics in cultivated mammalian cells. Nat. Biotechnol., 22, 1393-1398.
33. Agrawal, V. and Bal, M. (2012) Strategies for rapid production of therapeutic proteins in mammalian cells. BioProcess Int., 10, 32-48.
34. Kim, J.Y., Kim, Y.G., and Lee, G.M. (2012) CHO cells in biotechnology for production of recombinant proteins: current state and further potential. Appl. Microbiol. Biotechnol., 93, 917-930.
35. Racher, A.J., Tong, J.M., and Bonnerjea, J. (1999) Manufacture of Therapeutic Antibodies, in Biotechnology. Volume 5a. Recombinant Proteins, Monoclonal Antibodies, and Therapeutic Genes (eds A. Mountain, U.M. Ney, and D. Schomberg), Wiley-VCH Verlag GmbH, Weinheim, pp. 247-274.
36. Jayapal, K.P., Wlaschin, K.F., Hu, W.-S., and Yap, M.G.S. (2007) Recombinant protein therapeutics from CHO cells -20 years and counting. Chem. Eng. Prog., 103, 40-47.
37. Huang, Y.-M., Hu, W., Rustandi, E., Chang, K. et al. (2010) Maximizing productivity of CHO cell-based fed-batch culture using chemically defined media conditions and typical manufacturing equipment. Biotechnol. Prog., 26, 1400-1410.
38. Jiang, Z., Droms, K.A., Geng, Z., Casnocha, S.A. et al. (2012) Fed-batch cell culture process optimization. BioProcess Int., 10, 40-45.
39. Dorai, H., Ellis, D., Keung, Y.S., Campbell, M. et al. (2010) Combining highthroughput screening of caspase activity with anti-apoptosis genes for development of robust CHO production cell lines. Biotechnol. Prog., 26, 1367-1381.
40. Sinacore, M.S., Charlebois, T.S., Harrison, S., Brennan, S. et al. (1996) CHO DUKX cell lineages preadapted to growth in serum-free suspension culture enable rapid development of cell culture processes for the manufacture of recombinant proteins. Biotechnol. Bioeng., 52, 518-528.
41. Raju, T.S. (2003) Glycosylation variations with expression systems and their impact on biological activity of therapeutic immunoglobulins. BioProcess Int., 1, 44-53.
42. Wacker, C., Berger, C.N., Girard, P., and Meier, R. (2011) Glycosylation profiles of therapeutic antibody pharmaceuticals. Eur. J. Pharm. Biopharm., 79, 503-507.
43. Hossler, P., Khattak, S.F., and Li, Z.J. (2009) Optimal and consistent protein glycosylation in mammalian cell culture. Glycobiology, 199, 936-949.
44. Xu, X., Nagarajan, H., Lewis, N.E., Pan, S. et al. (2011) The genomic sequence of the Chinese hamster ovary (CHO)-K1 cell line. Nat. Biotechnol., 29, 735-741.
45. Raju, T.S., Briggs, J.B., Borge, S.M., and Jones, A.J. (2000) Species-specific variation in glycosylation of IgG: evidence for the species-specific sialylation and branchspecific galactosylation and importance for engineering recombinant glycoprotein therapeutics. Glycobiology, 10, 477-486.
46. Shields, R.L., Lai, J., Keck, R., O'Connell, L.Y. et al. (2002) Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcg RIII and antibodydependent cellular toxicity. J. Biol. Chem., 277, 26733-26740.
47. Shinkawa, T., Nakamura, K., Yamane, N., Shoji-Hosaka, E. et al. (2003) The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J. Biol. Chem., 278, 3466-3473.
48. Umaña, P., Jean-Mairet, J., Moudry, R., Amstutz, H., and Bailey, J.E. (1999) Engineered glycoforms of an antineuroblastoma IgG1 with optimised antibody-dependent cellular cytotoxic activity. Nat. Biotechnol., 17, 176-180.
49. von Horsten, H.H., Ogorek, C., Blanchard, V., Demmler, C. et al. (2010) Production of non-fucosylated antibodies by co-expression of heterologous GDP-6-deoxy-d-lyxo-4-hexulose reductase. Glycobiology, 20, 1607-1618.
50. Urlaub, G., Mitchell, P.J., Kas, E., Chasin, L.A. et al. (1986) Effect of gamma rays at the dihydrofolate reductase locus: deletions and inversions. Somatic Cell Mol. Genet., 12, 555-566.
51. Urlaub, G. and Chasin, L.A. (1980) Isolation of Chinese hamster cell mutants deficient in dihydrofolate reductase activity. Proc. Natl. Acad. Sci., USA, 77, 4216-4220.
52. Bailey, C.G., Tait, A.S., and Sunstrom, N.A. (2002) High-throughput clonal selection of recombinant CHO cells using a dominant selectable and amplifiable metallothionein-GFP fusion protein. Biotechnol. Bioeng., 80, 670-676.
53. Carroll, S. and Al-Rubeai, M. (2004) The selection of high-producing cell lines using flow cytometry and cell sorting. Expert Opin. Biol. Ther., 4, 1821-1829.
54. Porter, A.J., Racher, A.J., Preziosi, R., and Dickson, A.J. (2010) Strategies for selecting recombinant CHO cell lines for cGMP manufacturing: Improving the efficiency of cell line generation. Biotechnol. Prog., 26, 1455-1464.
55. Porter, A.J., Dickson, A.J., and Racher, A.J. (2010) Strategies for selecting recombinant CHO cell lines for cGMP manufacturing: realizing the potential in bioreactors. Biotechnol. Prog., 26, 1446-1454.
56. Ludwig, D.L. (2006) Mammalian expression cassette engineering for highlevel protein production. BioProcess Int., 4, 14-23.
57. Kim, S.J. and Lee, G.M. (1999) Cytogenetic analysis of chimeric antibodyproducing CHO cells in the course of dihydrofolate reductase-mediated gene amplification and their stability in the absence of selective pressure. Biotechnol Bioeng., 64, 741-749.
58. Lattenmayer, C., Loeschel, M., Steinfellner, W., Trummer, E. et al. (2006) Identification of transgene integration loci of different highly expressing recombinant CHO cell lines by FISH. Cytotechnology, 51, 171-182.
59. Yoshikawa, T., Nakanishi, F., Itami, S., Kameoka, D. et al. (2000) Evaluation of stable and highly productive gene amplified CHO cell line based on the location of amplified genes. Cytotechnology, 33, 37-46.
60. Hiragami-Hamada, K., Xie, S., Saveliev, A., Uribe-Lewis, S. et al. (2009) The molecular basis for stability of heterochromatin-mediated silencing in mammals. Epigen. Chromatin, 2, 14.
61. Foecking, M.K. and Hofstetter, H. (1986) Powerful and versatile enhancer-promoter unit for mammalian expression vectors. Gene, 45, 101-105.
62. Stephens, P.E. and Cockett, M.I. (1989) The construction of a highly efficient and versatile set of mammalian expression vectors. Nucleic Acids Res., 17, 7110.
63. Bebbington, C.R. (1991) Expression of antibody genes in nonlymphoid mammalian cells. METHODS, 2, 136-145.
64. Recillas-Targa, F., Pikaart, M.J., Burgess-Beusse, B., Bell, A.C. et al. (2002) Positioneffect protection and enhancer blocking by the chicken beta -globin insulator are separable activities. Proc. Natl. Acad. Sci. USA., 99, 6883-6888.
65. Gorman, C., Arope, S., Grandjean, M., Girod, P.A., and Mermod, N. (2009) Use of MAR Elements to increase the Production of Recombinant Proteins, in Cell Line Development (ed. M. Al-Rubeai), Springer, The Netherlands, pp. 1-32.
66. Harraghy, N., Buceta, M., Regamey, A., Girod, P.A., and Mermod, N. (2012) Using matrix attachment regions to improve recombinant protein production. Methods Mol. Biol., 801, 93-110.
67. Antoniou, M., Harland, L., Mustoe, T., Williams, S. et al. (2003) Transgenes encompassing dual-promoter CpG islands from the human TBP and HNRPA2B1 loci are resistant to heterochromatinmediated silencing. Genomics, 82, 269-279.
68. Nair, A., Jinger, X., and Hermiston, T. (2011) Effect of different UCOE-promoter combinations in creation of engineered cell lines for the production of Factor VIII. BMC Res. Notes, 4, 178.
69. Sautter, K. and Enenkel, B. (2005) Selection of high-producing CHO cells using NPT selection marker with reduced enzyme activity. Biotechnol. Bioeng., 89, 530-538.
70. Cacciatore, J.J., Chasin, L.A., and Leonard, E.F. (2010) Gene amplification and vector engineering to achieve rapid and high-level therapeutic protein production using the Dhfr-based CHO cell selection system. Biotechnol. Adv., 28, 673-681.
71. Hu, C.A., Lin, W.W., Obie, C., and Valle, D. (1999) Molecular enzymology of mammalian D1-pyrroline-5-carboxylate synthase: alternative splice donor utilization generates isoforms with different sensitivity to ornithine inhibition. J. Biol. Chem., 274, 6754-6762.
72. Leng, D.E. (1991) Succeed at scale up. Chem. Eng. Progress, 6, 23-31.
73. Merchuk, J.C. (1990) Why use air-lift bioreactors? TIBTECH, 8, 66-71.
74. Siegel, M.H. and Robinson, C.W. (1992) Applications of airlift gas liquid solid reactors in biotechnology. Chem. Eng. Sci., 47 (13/14), 3215-3229.
75. Smart, N.J. (1984) Gas lift fermenters: theory and practice. Laboratory Practice, July, 9-14.
76. Sola, C. and Godia, F. (1995) Scale up, in Biobioreactor System Design (eds J.A. Asenjo and J.C. Merchuk), Marcel Dekker, New York, pp. 511-552.
77. Varley, J. and Birch, J. (1999) Reactor design for large scale suspension animal cell culture. Cytotechnology, 29, 177-205.
78. Aunins, J.G. and Henzler, H.-J. (1993) Biotechnology, Bioprocessing, vol. 3 (ed. G. Stephanopoulos), VCH, Weinheim, pp. 19-281.
79. Kioukia, N., Nienow, A.W., Emery, A.N., and Al-Rubeai, M. (1992) The impact of fluid dynamics on the biological performance of free suspension animal cell culture: further studies. Trans. I Chem. E, 70, 143-148.
80. Hines, M. et al. (2010) Simple strategies to improve bioprocess pure culture processing. Pharmaceut. Eng., 30 (3), 1-11.
81. Delfosse, S. et al. (2013) Trends regarding viral barrier implementation in animal cell culture. Pharma. Bioprocess. , 1 (4), 351-430.
82. Chisti, Y. (1992) Assure bioreactor sterility. Chem. Eng. Prog., 88 (9), 80-85.
83. Bush, L. (2008) The environmental impact of disposables. BioPharm Int., 21 (11). vailable at http://www.biopharminternational.com/biopharm/From+the+Editor/The-Environmental-Impact-of-Disposables/ArticleStandard/Article/detail/566016.
84. Xie, L. and Wang, D.I. (1996) High cell density and high monoclonal antibody production through medium design and rational control in a bioreactor. Biotechnol. Bioeng., 51, 725-729.
85. Bibila, T.A. and Robinson, D.K. (1995) In pursuit of the optimal fed-batch process for monoclonal antibody production. Biotechnol. Prog., 11, 1-13.
86. Burky, J.E. et al. (2007) Protein-free fedbatch culture of non-GS NS0 cell lines for production of recombinant antibodies. Biotechnol. Bioeng., 96, 281-293.
87. Sauer, P.W., Burky, J.E., Wesson, M.C., Sternard, H.D., and Qu, L. (2000) A highyielding, generic fed-batch cell culture process for production of recombinant antibodies. Biotechnol. Bioeng., 67, 585-597.
88. Zhou, W., Chen, C.C., Buckland, B., and Aunins, J. (1997) Fed-batch culture of recombinant NS0 myeloma cells with high monoclonal antibody production. Biotechnol. Bioeng., 55, 783-792.
89. Huang, Y.M. et al. (2010) Maximizing productivity of CHO cell-based fed-batch culture using chemically defined media conditions and typical manufacturing equipment. Biotechnol. Prog., 26, 1400-1410.
90. Zhou, W. et al. (1996) Large scale production of recombinant mouse and rat growth hormone by fed-batch GS-NSO cell cultures. Cytotechnology, 22, 239-250.
91. Wong, D.C.F., Wong, K.T.K., Goh, L.T., Heng, C.K., and Yap, M.G.S. (2005) Impact of dynamic online fed-batch strategies on metabolism, productivity and N-glycosylation quality in CHO cell cultures. Biotechnol. Bioeng., 89, 164-177.
92. Kompala, D.S. and Ozturk, S.S. (2006) Cell Culture Technology for Pharmaceutical and Cell-Based Therapies (eds S.S. Ozturk and W.-S. Hu), Taylor & Francis, Boca Raton, FL, pp. 387-416.
93. Bodeker, B.G.D. et al. (1994) Animal Cell Technology, Products for Today, Prospects for Tomorrow (eds R.E. Spier, J.B. Griffiths, and W. Berthold), Butterworth-Heinemann, Oxford, pp. 580-583.
94. Deo, Y.M., Mahadevan, M.D., and Fuchs, R. (1996) Practical considerations in operation and scale-up of spin-filter based bioreactors for monoclonal antibody production. Biotechnol. Prog., 12, 57-64.
95. Lambert, K.J. and Birch, J.R. (1985) Cell Growth Media, in Animal Cell Biotechnology., vol. 1 (ed. R.E. Spieret al.), Academic Press, New York, pp. 85-122.
96. Ballez, J.S., Mols, J., Burteau, C., Agathos, S.N., and Schneider, Y.J. (2004) Plant protein hydrolysates support CHO-320 cells proliferation and recombinant IFNgamma production in suspension and inside microcarriers in protein-free media. Cytotechnology, 44, 103-114.
97. Ma, N. et al. (2009) A single nutrient feed supports both chemically defined NS0 and CHO fed-batch processes: improved productivity and lactate metabolism. Biotechnol. Prog., 25, 1353-1363.
98. Spens, E. and Haggstrom, L. (2007) Defined protein and animal componentfree NS0 fed-batch culture. Biotechnol. Bioeng., 98, 1183-1194.
99. Wong, V.V., Ho, K.W., and Yap, M.G. (2004) Evaluation of insulin-mimetic trace metals as insulin replacements in mammalian cell cultures. Cytotechnology, 45, 107-115.
100. Dempsey, J. et al. (2003) Improved fermentation processes for NS0 cell lines expressing human antibodies and glutamine synthetase. Biotechnol. Prog., 19, 175-178.
101. Zhu, M.M. et al. (2005) Effects of elevated pCO2 and osmolality on growth of CHO cells and production of antibody-fusion protein B1: a case study. Biotechnol. Prog., 21, 70-77.
102. Chisti, Y. (2000) Animal-cell damage in sparged bioreactors. Trends Biotechnol., 18, 420-432.
103. Papoutsakis, E.T. (1991) Media additives for protecting freely suspended animal cells against agitation and aeration damage. Trends Biotechnol., 9, 316-324.
104. Murhammer, D.W. (2009) Polyols - Cell Protection, in Encyclopedia of Industrial Biotechnology: Bioprocess, Bioseparation, and Cell Technology (ed. M.C. Flickinger), John Wiley & Sons, Inc., Hoboken.
105. Jiang, Z. and Sharfstein, S.T. (2008) Sodium butyrate stimulates monoclonal antibody over-expression in CHO cells by improving gene accessibility. Biotechnol. Bioeng., 100, 189-194.
106. Chen, F. (2011) et al.The combined effect of sodium butyrate and low culture temperature on the production, sialylation, and biological activity of an antibody produced in CHO cells. Biotechnol. Bioprocess. Eng., 16, 1157-1165.
107. Sung, Y.H. and Lee, G.M. (2005) Enhanced human thrombopoietin production by sodium butyrate addition to serum-free suspension culture of bcl-2-overexpressing CHO cells. Biotechnol. Prog., 21, 50-57.
108. Carvell, J.P. and Dowd, J.E. (2006) Online measurements and control of viable cell density in cell culture manufacturing processes using radiofrequency impedance. Cytotechnology, 50, 35-48.
109. Pattison, R.N., Swamy, J., Mendenhall, B., Hwang, C., and Frohlich, B.T. (2000) Measurement and control of dissolved carbon dioxide in mammalian cell culture processes using an in situ fiber optic chemical sensor. Biotechnol. Prog., 16, 769-774.
110. Teixeira, A.P., Duarte, T.M., Carrondo, M.J., and Alves, P.M. (2011) Synchronous fluorescence spectroscopy as a novel tool to enable PAT applications in bioprocesses. Biotechnol. Bioeng., 108, 1852-1861.
111. Abu-Absi, N.R. et al. (2011) Real time monitoring of multiple parameters in mammalian cell culture bioreactors using an in-line Raman spectroscopy probe. Biotechnol. Bioeng., 108, 1215-1221.
112. Yoon, S.K., Hwang, S.O., and Lee, G.M. (2004) Enhancing effect of low culture temperature on specific antibody productivity of recombinant Chinese hamster ovary cells: clonal variation. Biotechnol. Prog., 20, 1683-1688.
113. Nam, J.H., Zhang, F., Ermonval, M., Linhardt, R.J., and Sharfstein, S.T. (2008) The effects of culture conditions on the glycosylation of secreted human placental alkaline phosphatase produced in Chinese hamster ovary cells. Biotechnol. Bioeng., 100, 1178-1192.
114. Trummer, E. et al. (2006) Process parameter shifting: Part II. Biphasic cultivation-A tool for enhancing the volumetric productivity of batch processes using Epo-Fc expressing CHO cells. Biotechnol. Bioeng., 94, 1045-1052.
115. Trummer, E. et al. (2006) Process parameter shifting: Part I. Effect of DOT, pH, and temperature on the performance of Epo-Fc expressing CHO cells cultivated in controlled batch bioreactors. Biotechnol. Bioeng., 94, 1033-1044.
116. Bollati-Fogolin, M. et al. (2005) Temperature reduction in cultures of hGM-CSF-expressing CHO cells: effect on productivity and product quality. Biotechnol. Prog., 21, 17-21.
117. Nienow, A.W. et al. (1996) Homogenisation and oxygen transfer rates in large agitated and sparged animal cell bioreactors: Some implications for growth and production. Cytotechnology, 22, 87-94.
118. Backer, M.P., Metzger, L.S., Slaber, P.L., Nevitt, K.L., and Boder, G.B. (1988) Largescale production of monoclonal antibodies in suspension culture. Biotechnol. Bioeng., 32, 993-1000.
119. Borys, M.C. et al. (2010) Effects of culture conditions on N-glycolylneuraminic acid (Neu5Gc) content of a recombinant fusion protein produced in CHO cells. Biotechnol. Bioeng., 105, 1048-1057.
120. Wayte, J. et al. (1997) pH: Effects on growth and productivity of cell lines producing monoclonal antibodies: control in large-scale fermenters. Genet. Eng. Biotechnol., 17, 125-132.
121. Osman, J.J., Birch, J., and Varley, J. (2001) The response of GS-NS0 myeloma cells to pH shifts and pH perturbations. Biotechnol. Bioeng., 75, 63-73.
122. Osman, J.J., Birch, J., and Varley, J. (2002) The response of GS-NS0 myeloma cells to single and multiple pH perturbations. Biotechnol. Bioeng., 79, 398-407.
123. Ozturk, S.S. and Palsson, B.O. (1991) Growth, metabolic, and antibody production kinetics of hybridoma cell culture: 2. Effects of serum concentration, dissolved oxygen concentration, and medium pH in a batch reactor. Biotechnol. Prog., 7, 481-494.
124. Borys, M.C., Linzer, D.I., and Papoutsakis, E.T. (1993) Culture pH affects expression rates and glycosylation of recombinant mouse placental lactogen proteins by Chinese hamster ovary (CHO) cells. Biotechnology (N.Y.), 11, 720-724.
125. Fleischaker, R.J. and Sinskey, A.J. (1981) Oxygen demand and supply in cell culture. Eur. J. Appl. Microbiol. Biotechnol., 12, 193-197.
126. Boraston, R., Thompson, P.W., Garland, S., and Birch, J.R. (1983) Growth and oxygen requirements of antibody producing mouse hybridoma cells in suspension culture. Dev. Biol Stand., 55, 103-111.
127. Restelli, V. et al. (2006) The effect of dissolved oxygen on the production and the glycosylation profile of recombinant human erythropoietin produced from CHO cells. Biotechnol. Bioeng., 94, 481-494.
128. Ge, X., Kostov, Y., and Rao, G. (2005) Lowcost noninvasive optical CO2 sensing system for fermentation and cell culture. Biotechnol. Bioeng., 89, 329-334.
129. Mostafa, S.S. and Gu, X. (2003) Strategies for improved dCO2 removal in large-scale fed-batch cultures. Biotechnol. Prog., 19, 45-51.
130. Dezengotita, V.M., Schmelzer, A.E., and Miller, W.M. (2002) Characterization of hybridoma cell responses to elevated pCO(2) and osmolality: intracellular pH, cell size, apoptosis, and metabolism. Biotechnol. Bioeng., 77, 369-380.
131. Gray, D.R., Chen, S., Howarth, W., Inlow, D., and Maiorella, B.L. (1996) CO(2) in large-scale and high-density CHO cell perfusion culture. Cytotechnology, 22, 65-78.
132. Kim, T.K., Ryu, J.S., Chung, J.Y., Kim, M.S., and Lee, G.M. (2000) Osmoprotective effect of glycine betaine on thrombopoietin production in hyperosmotic Chinese hamster ovary cell culture: clonal variations. Biotechnol. Prog., 16, 775-781.
133. Bogdan, B. and Villiger, R. (2010) Valuation in Life Sciences: A Practical Guide 3rdedn, Springer, Heidelberg.
134. Pollock, J., Bolton, G., Coffman, J., Ho, S.V. et al. (2013) Optimising the design and operation of semi-continuous affinity chromatography for clinical and commercial manufacture. J. Chromatogr. A, 1284, 17-27.
135. Farid, S.S. (2007) Process economics of industrial monoclonal antibody manufacture. J. Chromatogr. B., 848, 8-18.
136. George, E.D. and Farid, S.S. (2008) Strategic biopharmaceutical portfolio development: an analysis of constraintinduced implications. Biotechnol. Prog., 24 (3), 698-713.
137. Anicetti, V. (2009) Biopharmaceutical processes: a glance into the 21st century. BioProcess Int., 7 (S1), 4-11.
138. Scolnik, P.A. (2009) mAbs: A business perspective. mAbs, 1 (2), 179-184.
139. Farid, S.S., Washbrook, J., and Titchener-Hooker, N.J. (2005) Decision-support tool for assessing biomanufacturing strategies under uncertainty: stainless steel versus disposable equipment for clinical trial material preparation. Biotechnol. Prog., 21 (2), 486-497.
140. Farid, S.S., Washbrook, J., and Titchener-Hooker, N.J. (2007) Modelling biopharmaceutical manufacture: design and implementation of SimBiopharma. Comput. Chem. Eng., 31, 1141-1158.
141. Brown, M.E., Renner, G., Field, R.P., and Hassell, T. (1992) Process development for the production of recombinant antibodies using the glutamine synthetase (GS) system. Cytotechnology, 9, 231-236.
142. Birch, J.R., Bonnerjea, J., Flatman, S., and Vranch, S. (1995) Production of Monoclonal Antibodies, in Monoclonal Antibodies: Principles and Application (eds J.R. Birch and E.S. Lennox), Wiley-Liss Inc., New York, pp. 231-265.
143. Werner, R.G. (2005) The development and production of biopharmaceuticals: technological and economic success factors. BioProcess Int., 3 (9), S6-S15.
144. Huang, Y.-M., Hu, W., Rustandi, E., Chang, K. et al. (2010) Maximizing productivity of CHO cell-based fed-batch culture using chemically defined media conditions and typical manufacturing equipment. Biotechnol. Prog., 26, 1400-1410.
145. Li, F., Vijayasankaran, N., Shen, A., Kiss, R., and Amanullah, A. (2010) Cell culture processes for monoclonal antibody production. mAbs, 2 (5), 466-477.
146. Pacis, E., Vijayasankaran, N., Gawlitzek, M., Amanullah, A., and Li, F. (2010) Systematic approaches to develop chemically defined cell culture feed media. BioPharm Int., 23 (11), 22-32.
147. Jostock, T. (2011) Expression of antibody in mammalian cells. Cell Eng., 7, 1-24.
148. Werner, R.G. (2004) Economic aspects of commercial manufacture of biopharmaceuticals. J. Biotechnol., 113, 171-182.
149. Li, F., Zhou, J.X., Yang, X., Tressel, T., and Lee, B. (2005) Current therapeutic antibody production and process optimization. BioProcess. J., 4, 1-8.
150. Ultee, M.E. and Rea, D.W. (1999) Antibody Purification, in Encyclopaedia of Bioprocess Technology: Fermentation, Biocatalysis and Bioseparation, vol. 1 (eds M.C. Flickinger and S.W. Drew), John Wiley & Sons, Inc., New York.
151. Carson, K.L. (2005) Flexibility- the guiding principle for antibody manufacturing. Nat. Biotechnol., 23, 1054-1058.
152. Kelley, B. (2007) Very large scale monoclonal antibody purification: the case for conventional unit operations. Biotechnol. Prog., 23 (5), 995-1008.
153. Sinclair, A. and Monge, M. (2009) Disposables cost contributions: a sensitivity analysis. Biopharm. Int., 22 (4), 14-18.
154. Levine, H.L., Stock, R., Lilja, J.E., Gaasvik, Á. et al. (2013) Single-use technology and modular construction. BioProcess Int., 11 (S4), 40-45.
155. Pollock, J., Ho, S.V., and Farid, S.S. (2013) Fed-batch and perfusion culture processes: operational, economic and environmental feasibility under uncertainty. Biotechnol. Bioeng., 110 (1), 206-219.
156. Farid, S.S., Washbrook, J., and Titchener-Hooker, N.J. (2005) Combining multiple quantitative and qualitative goals when assessing biomanufacturing strategies under uncertainty. Biotechnol Prog., 21 (4), 1183-1191.
157. Lim, A.C., Washbrook, J., Titchener-Hooker, N.J., and Farid, S.S. (2006) A computer-aided approach to compare the production economics of fed-batch and perfusion culture under uncertainty. Biotechnol. Bioeng., 93 (4), 687-697.
158. Crowley, J., Wubben, M., and Coco Martin, J.M. (2008) Process for cell culturing by continuous perfusion and alternating tangential flow. Pat. 20080131934.
159. Shevitz, J. (2000) Fluid filtration system. Pat. 6544424.
160. Stonier, A., Simaria, A.S., Smith, M., and Farid, S.S. (2012) Decisional tool to assess current and future process robustness in an antibody purification facility. Biotechnol. Prog., 28 (4), 1019-1028.
161. Simaria, A.S., Turner, R., and Farid, S.S. (2012) A multi-level metaheuristic algorithm to optimise antibody purification processes at the bioprocessbusiness interface. Biochem. Eng. J., 69, 144-154.